---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-115675"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:51:03.967161+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rhythm Q3 2022: IMCIVREE revenue $4.3M; net loss $40.9M; cash $347.8M

## Summary
- Product revenue $4.3M vs $1.0M YoY; net loss $40.9M ($0.79/share) vs $35.1M ($0.70).
- More than 120 IMCIVREE prescriptions written for BBS since FDA approval; 40+ approved for reimbursement.
- FDA Breakthrough Therapy Designation for setmelanotide in hypothalamic obesity; Phase 3 trial to start early 2023.
- Completed public offering netting $131.2M; extended cash runway into 2025.
- Appointed Dana Washburn as SVP Clinical Development; EC expanded approval for IMCIVREE in BBS.

## SEC filing metadata
- accession: 0001104659-22-115675
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000110465922115675/0001104659-22-115675-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000110465922115675/tm2229796d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-115675
- JSON: https://secwatch.observer/filing/0001104659-22-115675.json
- Plain text: https://secwatch.observer/filing/0001104659-22-115675.txt

## Key facts
- Earnings Releases
  RHYTHM PHARMACEUTICALS, INC. reported financial results for quarter ended September 30, 2022.
  - Period: quarter ended September 30, 2022
  - Result: reported results
  source text: On November 8, 2022, Rhythm Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649904/000110465922115675/0001104659-22-115675-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.